AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
COLPAL.NS

Colgate-Palmolive (India) Limited (COLPAL.NS) fair value

Consumer Defensive · Household & Personal Products · NSE · India
₹1605.00-4.75%
Market cap ₹436.5BNext earnings 2026-10-22Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionColgate-Palmolive (India) Limited (COLPAL.NS)
Fair value
Not available
ACCE price target
₹1569
Rating
Not rated
Horizon
12 months
ACCE price target published on 23 Oct 2026, 01:53 CEST.
Price used: ₹1605 at the close on 23 Oct 2026, 12:00 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
52
out of 100
P/E
32.1x
forward 27.8x
1-year return
-29.8%
Dividend yield
2.85%

Colgate-Palmolive (India) Limited in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Colgate-Palmolive (India) makes Colgate toothpaste and toothbrushes, Palmolive soaps and Protekt and Sensodyne-style oral care lines sold through a dense distribution network across Indian towns and villages. Its advantage is brand trust in oral care plus a distribution reach that smaller competitors struggle to match, which supports a 68.9% gross margin and a 27.7% operating margin. Revenue grew 11.8%, and with a forward P/E of 29.0 against a trailing 34.0, the market is pricing in earnings growth. The case for a closer look is that this is a high-margin staple compounding through India's rising per-capita spend on oral hygiene, but the multiple leaves little room for a stumble in volume growth, so the work is in checking whether that 11.8% top-line pace holds.

AI-assisted·How I use AIWritten Oct 23, 2026

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where COLPAL.NS's valuation models land
Price
₹1605.00
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
-9.4%
1 month
-14.9%
3 months
-23.1%
6 months
-26.1%
YTD
-23.3%
1 year
-29.8%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:53 CESTACCE price target₹1569first publication₹1685

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in INR. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full COLPAL.NS page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth52Value40Quality100Momentum17Total52
Valuation
Trailing P/E
32.1x
Forward P/E
27.8x
PEG
4.96
P/B
no data
EV / Revenue
no data
Book value/sh
no data
Enterprise value
no data
Profitability
ROE
no data
FCF yield
no data
ROIC
no data
Health and risk
Debt / equity
0.03
Dividend yield
2.85%
Beta
no data

Price

-28.3% · 1Y

Ask anything about COLPAL.NS

Answered from Colgate-Palmolive (India) Limited fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 17% of peers
low 14.4x32.1xhigh 327.1x
Div yieldbetter than 67% of peers
low 1.5%2.8%high 5.9%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
COLPAL.NS Colgate-Palmolive (India) Limited₹1605.00--32.1x-10052
4527.T Rohto Pharmaceutical Co.,Ltd.¥2851.50--20.0x10.9%6766
IPAR Interparfums Inc. Common Stock$116.07$9621% above22.0x19.1%7762
KIMBERA.MX Kimberly-Clark de MexicoMXN 37.90MXN 4515% below14.4x147.5%7552
4967.T Kobayashi Pharmaceutical Co., Ltd.¥7150.00--327.1x0.8%4647
ITP.PA Interparfums SA€34.50€2445% above25.8x17.1%8359
4912.T Lion Corporation¥1831.00--17.7x9.7%6770

Sector report card

Where COLPAL.NS ranks against its sector peers on each metric.

Computing percentiles…